

**Supplemental Table 1 Baseline characteristics**

<b>Variables</b>	<b>Control, n = 41</b>	<b>Cancer patients, n = 130</b>	<b>P value</b>	<b>Survivors, n = 106</b>	<b>Non-survivors, n = 24</b>	<b>P value</b>
Age in yr	63.46 ± 9.00	66.88 ± 11.51	0.051	65.25 ± 11.43	74.13 ± 8.87	0.001
Female	20 (48.8)	46 (35.4)	0.124	41 (38.7)	5 (20.8)	0.099
BMI in kg/m <sup>2</sup>	22.84 ± 3.12	23.11 ± 3.67	0.670	23.07 ± 3.78	23.30 ± 3.21	0.782
SBP in mmHg	135.51 ± 22.07	129.31 ± 18.33	0.067	130.78 ± 18.51	122.79 ± 16.68	0.053
DBP in mmHg	84.17 ± 12.57	76.45 ± 11.61	< 0.001	77.68 ± 11.74	71.00 ± 9.44	0.010
Heart rate in bpm	79.66 ± 13.48	79.73 ± 12.53	0.975	79.19 ± 12.49	82.13 ± 12.68	0.302
Laboratory parameters						
Hemoglobin in g/L	134.82 ± 13.38	117.65 ± 25.51	< 0.001	120.41 ± 24.40	115.47 ± 27.21	0.009
RDW as %	13.05 ± 0.93	15.41 ± 5.65	< 0.001	15.48 ± 6.13	15.09 ± 2.70	0.763

WBC as $\times 10^9/L$	6.69 $\pm$ 2.36	6.37 $\pm$ 2.06	0.414	6.23 $\pm$ 1.76	7.03 $\pm$ 3.03	0.085
Neutrophil ratio as %	62.98 $\pm$ 10.62	34.75 $\pm$ 30.24	< 0.001	32.68 $\pm$ 29.51	43.86 $\pm$ 32.36	0.102
C-reactive protein in mg/L	10.41 $\pm$ 27.29	4.69 $\pm$ 10.84	0.312	4.62 $\pm$ 10.65	5.07 $\pm$ 12.23	0.876
Creatinine in $\mu\text{mol/L}$	74.89 $\pm$ 19.02	81.22 $\pm$ 25.20	0.141	79.35 $\pm$ 24.21	89.47 $\pm$ 28.30	0.076
LDL-C in mmol/L	3.20 $\pm$ 0.59	3.11 $\pm$ 0.86	0.455	3.19 $\pm$ 0.85	2.71 $\pm$ 0.81	0.019
Aspartate transaminase in U/L	22.30 $\pm$ 9.75	22.07 $\pm$ 12.36	0.913	22.41 $\pm$ 13.31	20.60 $\pm$ 6.74	0.519
Alanine transaminase in U/L	18.64 $\pm$ 10.76	18.82 $\pm$ 13.07	0.929	19.44 $\pm$ 13.58	16.08 $\pm$ 10.33	0.257
Total bilirubin in $\mu\text{mol/L}$	11.16 $\pm$ 5.85	12.52 $\pm$ 5.73	0.203	16.70 $\pm$ 5.11	11.73 $\pm$ 8.04	0.469
Direct bilirubin in $\mu\text{mol/L}$	2.17 $\pm$ 1.31	2.59 $\pm$ 1.71	0.166	2.58 $\pm$ 1.64	2.62 $\pm$ 2.02	0.926
CKMB in U/L	12.01 $\pm$ 9.07	18.32 $\pm$ 27.26	0.193	16.71 $\pm$ 25.04	25.48 $\pm$ 35.35	0.184
Troponin I in $\mu\text{g/L}$				0.009 $\pm$ 0.016	0.134 $\pm$ 0.467	0.006
Myoglobin in ng/mL	38.39 $\pm$ 23.79	49.28 $\pm$ 37.07	0.160	46.82 $\pm$ 31.35	60.13 $\pm$ 55.39	0.113

CEA in ng/mL	2.06 (1.47, 2.65)	3.33 (2.09, 9.51)	< 0.001	3.13 (1.91, 7.66)	7.78 (3.05, 22.47)	0.002
CA125 in U/mL	7.90 (6.13, 11.48)	12.00 (8.65, 18.05)	< 0.001	11.40 (8.45, 17.20)	13.45 (10.10, 29.00)	0.064
CA199 in U/mL	7.00 (4.00, 12.76)	8.59 (4.09, 22.37)	0.231	7.32 (4.10, 21.95)	15.84 (3.90, 47.26)	0.184
Potassium in mmol/L	3.87 ± 0.32	3.94 ± 0.39	0.326	3.93 ± 0.37	3.97 ± 0.48	0.662
Ejection fraction as %	68.32 ± 5.07	66.48 ± 6.40	0.107	66.50 ± 6.38	66.40 ± 6.59	0.947
Left atrium in mm	29.50 ± 3.09	31.94 ± 5.17	< 0.001	31.67 ± 5.25	33.13 ± 4.73	0.215
LVEDD in mm	43.24 ± 3.61	45.98 ± 5.21	< 0.001	45.64 ± 5.09	47.50 ± 5.60	0.115
Interventricular septum in mm	9.47 ± 1.35	10.05 ± 1.74	0.060	9.91 ± 1.59	10.71 ± 2.22	0.041
LVPW in mm	9.08 ± 1.02	9.60 ± 1.51	0.016	9.42 ± 1.29	10.42 ± 2.06	0.031
Medical history						
Coronary artery disease	NA	14 (10.8)		11 (10.4)	3 (12.5)	1.000
Previous myocardial infarction	NA	2 (1.5)		2 (1.9)	0 (0)	1.000
Hypertension	23 (56.1)	62 (47.7)	0.348	47 (44.3)	15 (62.5)	0.108
Atrial fibrillation	NA	7 (5.4)		6 (5.7)	1 (4.2)	1.000

Diabetes mellitus	0 (0)	20 (15.4)	0.004	16 (15.4)	4 (16.7)	1.000
Chronic kidney disease	NA	1 (0.8)		1 (0.9)	0 (0)	1.000
Peripheral vascular disease	0 (0)	4 (3.1)	0.574	4 (3.8)	0 (0)	1.000
Cerebral infarction	NA	12 (9.2)		10 (9.4)	2 (8.3)	1.000
Medications						
Preoperative chemotherapy	NA	16 (12.3)		12 (11.3)	4 (16.7)	0.707
Aspirin	5 (12.2)	5 (3.8)	0.047	5 (4.7)	0 (0)	0.583
Clopidogrel	2 (4.9)	6 (4.6)	1.000	5 (4.7)	1 (4.2)	1.000
Betaloc	4 (9.8)	11 (8.5)	1.000	10 (9.4)	1 (4.2)	0.666
Statin	9 (22.0)	9 (6.9)	0.006	8 (7.5)	1 (4.2)	0.886
ACEI/ARB	10 (24.4)	22 (16.9)	0.285	18 (17.0)	4 (16.7)	1.000
CCB	13 (31.7)	29 (22.3)	0.223	25 (23.6)	4 (16.7)	0.643
Metformin	0 (0)	5 (3.8)	0.339	2 (1.9)	3 (12.5)	0.043
Conventional ECG						
ST-T changes	1 (2.5)	20 (15.7)	0.054	12 (11.7)	8 (33.3)	0.009
Left BBB	0 (0)	1 (0.8)	1.000	1 (1.0)	0 (0)	1.000
Right BBB	0 (0)	13 (10.2)	0.040	9 (8.7)	4 (16.7)	0.435
APB	0 (0)	14 (11.0)	0.042	9 (8.7)	5 (20.8)	0.088
PVC	1 (2.5)	27 (21.3)	0.012	21 (20.4)	6 (25.0)	0.619
Sinus bradycardia	4 (10.0)	24 (18.9)	0.284	20 (19.4)	4 (16.7)	0.984

Sinus tachycardia	3 (7.5)	3 (2.4)	0.300	3 (2.9)	0 (0)	1.000
AF	0 (0)	7 (5.5)	0.352	5 (4.9)	2 (8.3)	0.860
First degree A-V block	0 (0)	11 (8.7)	0.068	8 (7.8)	3 (12.5)	0.734
LVH	5 (12.5)	18 (14.2)	0.789	11 (10.7)	7 (29.2)	0.019
Q wave	1 (2.5)	12 (9.4)	0.275	11 (10.7)	1 (4.2)	0.552
Relative clinical index						
Smoke	7 (17.1)	15 (11.5)	0.356	11 (10.4)	4 (16.7)	0.605
Lee score $\geq 2$	NA	2 (1.5)		0 (0)	2 (8.3)	0.033
Advanced tumor stage $\geq$ III	NA	NA	NA	40 (37.7)	17 (70.8)	0.003
PVC/24 h	1.0 (0, 6.5)	14.0 (1, 405.0)	< 0.001	9.0 (0, 259.3)	150.5 (7.3, 1690.5)	0.020
NSVT $\geq 1$	0 (0)	10 (7.7)	0.120	7 (6.6)	3 (12.5)	0.579

ACEI: Angiotensin converting enzyme inhibitor; AF: Atrial fibrillation; APB: Atrial premature beat; ARB: Angiotensin receptor antagonist; BBB: Bundle branch block; BMI: Body mass index; bpm: Beats per minute; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; CCB: Calcium channel blockers; CEA: Carcinoembryonic antigen; CKMB: Creatine kinase-MB; DBP: Diastolic blood pressure; ECG: Electrocardiogram; First degree A-V block: First degree atrioventricular block; LDL-C: Low-density lipoprotein cholesterol; LVEDD: Left ventricular end-diastolic dimension; LVH: Left ventricular hypertrophy; LVPW: Left ventricular posterior wall; NSVT: Non-sustained ventricular tachycardia; PVC: Premature ventricular contraction; RDW: Red cell distribution width; SBP: Systolic blood pressure; WBC: White blood cell.